Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Wednesday, February 12, 2025, at 2:40 p.m.